Lantern Pharma Narrows Loss in Q2

Lantern Pharma (NASDAQ:LTRN), a biotech focused on AI-enabled precision oncology, released its earnings for the quarter ended June 30, 2025, on August 13, 2025. Lantern Pharma reported a GAAP net loss per share of ($0.40) in Q2 2025, and marking an improvement from ($0.46) per share (GAAP) in Q2 2024. As expected for a clinical-stage biotech, no product revenue was recorded. Research and development costs (GAAP) declined compared to Q2 2024, and Lantern Pharma reported $15.9 million in cash, cash equivalents, and marketable securities as of Q2 2025. These results point to effective cost controls as Lantern Pharma advances its pipeline, but continued cash burn and a lack of near-term revenue or regulatory catalysts remain key watchpoints. Source: Analyst estimates for the quarter provided by FactSet. Lantern Pharma is a clinical-stage biotechnology company specializing in artificial intelligence (AI) and machine learning to develop targeted cancer therapies. Its main approach leverages its RADR platform—a system designed to analyze vast datasets to identify and accelerate promising oncology drug candidates.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool